Search
Novo Nordisk A/S
NVOAdd to Watchlist
40.300USD
-1.880-4.46%
Close 11-04 16:00（ET）
177.80BMarket Cap
9.42P/E TTM
After-hours 19:07 (ET)39.980USD-0.360-0.89%
After-hours 19:07 (ET)Novo Nordisk A/S (NVO) Stock Price Target & Forecast
Analyst Rating
Based on 13 analysts giving stock ratings to Novo Nordisk A/S in the past month.
Hold
1 Strong Buy
1 Buy
10 Hold
1 Sell
0 Strong Sell
Target Price
48.523USD+21.31%
NVO Analyst Recommendation Trends
In the current month, NVO has received 1 Buy Ratings, 10 Hold Ratings, and 1 Sell Ratings. NVO average Analyst price target in the last month is 48.523.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
1
1
2
2
2
2
2
1
1
1
2
2
2
2
2
4
10
10
10
10
10
10
10
7
0
0
0
0
0
0
0
0
1
1
0
0
0
0
0
1
13
13
14
14
14
14
14
13
NVO Analyst Rating for Peer Comparison
Updated: Nov 5, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Biogen Inc
BIIB
8
16
12
1
0
37
Amgen Inc
AMGN
4
9
19
3
1
36
Vertex Pharmaceuticals Inc
VRTX
10
17
5
0
1
33
Eli Lilly and Co
LLY
10
19
3
1
0
33
Alnylam Pharmaceuticals Inc
ALNY
7
17
8
0
0
32
AbbVie Inc
ABBV
8
18
6
0
0
32
Merck & Co Inc
MRK
7
16
8
0
0
31
Neurocrine Biosciences Inc
NBIX
13
14
4
0
0
31
Gilead Sciences Inc
GILD
7
18
5
0
0
30
Bristol-Myers Squibb Co
BMY
5
6
18
1
0
30
Financial Forecasting
Based on analysts' estimates, NVO EPS is projected to reach 0.763 in FY2026Q3, following reported EPS of 0.736 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
0.86
0.92
0.75
0.76
0.71
Actual
0.94
1.71
0.74
--
--
Surprise
+9.77%
+86.36%
-1.51%
--
--
FAQs
What is Novo Nordisk A/S's expected revenue for the next quarter?
Novo Nordisk A/S's expected revenue is 11.06B.
What is Novo Nordisk A/S's price target?
Analysts forecast that Novo Nordisk A/S's price target is USD 48.52, with the highest forecast at USD 65.00 and the lowest forecast at USD 40.00.
How have Novo Nordisk A/SNVO's recent earnings per share performed?
The market expectation was USD 0.74, while Novo Nordisk A/SNVO's earnings per share (EPS) for the previous quarter was USD 1.71. EPS for the next quarter is expected at USD 0.76.
What is the analyst rating for Novo Nordisk A/S?
Based on the ratings of Novo Nordisk A/S's stock from 13 analysts, most analysts support a signal_hold trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as signal_hold. Please note that this is not trading advice. You still need to conduct your own analysis.